NCT03161561

Mechanisms and Impact of Bacterial Colonisation in COPD

Completed NA Last updated 15 February 2019

What this trial tests

NA trial testing capacity of primary phagocytes in COPD in 37 participants. Completed in 1 February 2018.

Timeline

16 November 2011

Primary endpoint
1 February 2018

1 February 2018

Quick facts

Lead sponsor	Sheffield Teaching Hospitals NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	37
Start date	16 November 2011
Primary completion	1 February 2018
Estimated completion	1 February 2018
Sites	1 location across United Kingdom

Drugs / interventions tested

• capacity of primary phagocytes

Conditions studied

• COPD — all drugs for COPD →

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Who can join

Adults 18 to 69, any sex, with COPD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COPD is a leading cause of lung disease and a common cause of hospitalisation, time off work and death. Smoking is the major factor associated with development of COPD. Nevertheless why some people develop COPD while others, including many smokers do not, is poorly understood. A central feature of COPD is accumulation of a particular type of white blood cell, the neutrophil, which is a key component in defence against bacterial infection in the lung airway. As disease progresses the small airways of many patients with COPD start to accumulate bacteria, which are normally lacking in the small airways of healthy individuals or smokers who lack COPD. The accumulation of bacteria in the smaller airways of many patients with COPD may be important to the development of the disease. Researchers will test if blood cells, which normally ingest and kill bacteria, have a reduced ability to perform this function in patients with COPD and whether the clearance of these blood cells after they have performed their role in protecting against infection is impaired. Researchers will relate these findings to the clinical features of COPD in a well-defined group of patients who have had extensive characterisation of their disease. In particular, researchers will relate this defect to the presence of frequent flares of disease, which lead to symptoms of wheezing and shortness of breath. Comparison will be made between blood cells obtained from the lung and from he blood to determine if the alterations are specific to the lung. Researchers will identify particular molecular alterations in the way these blood cells respond to bacteria and determine whether they can correct these alterations using agents, which are used to treat a range of different medical conditions, but which they predict might correct these alterations in function. The aim of this programme of work is ultimately to identify new ways in which to treat COPD and the agents, which the researchers demonstrate have the greatest potential to correct the abnormalities in cell function of patients with COPD, would in the future be studied in clinical trials.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.